TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

December 20, 2023

https://www.globenewswire.com/news-release/2023/12/20/2799215/10391/en/TRACON-Pharmaceuticals-Provides-Positive-Update-on-Ongoing-ENVASARC-Pivotal-Phase-2-Trial.html

Objective Response Rate by investigator review increased to 15% since interim analysis in September

Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024

Read more at globenewswire.com

Related news for (TCON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.